influenza%20(pediatric)
INFLUENZA (PEDIATRIC)
Influenza may present as a mild respiratory illness similar to the common cold or it may present without characteristic signs and symptoms.
The main type of influenza virus are types A, B & C virus. Types A&B are the main causes of influenza outbreaks.
Patient may appear flushed and have pain on eye movement. Non-exudative pharyngitis, scattered rales or rhonchi may be present.

Influenza%20(pediatric) Treatment

Antiviral Agents

  • Option for the control of influenza, but should not be used as a substitute to influenza vaccination

Prophylaxis

  • Antiviral agents (eg Oseltamivir, Zanamivir) may be used to prevent spread of influenza during an influenza outbreak in an institutionalized setting
  • May be used in persons who cannot be vaccinated due to contraindications to vaccine
    • Do not start until influenza epidemic has begun and stop only when epidemic is over
  • May be used in persons at high-risk for complications who have been vaccinated after an outbreak of influenza has begun
    • Give for 2 weeks starting from day of vaccination to give sufficient time for immunity to develop
  • Postexposure chemoprophylaxis should only be used if agents can be given within 48 hours of exposure

Treatment

  • When used within 48 hours of symptom onset, antiviral agents may reduce the duration of symptoms
    • Should not be used if there is uncertainty about diagnosis or if bacterial infection cannot be ruled out
    • Administration of antiviral treatment may be considered in very ill or high-risk suspected influenza patients even without confirmed tests if:
      • Currently admitted
      • Categorized as severe, complicated, or with progressive disease
      • At high risk for complications (ie immunocompromised, <2 years of age, with comorbidities)
      • Receiving long-term Aspirin treatment
  • None of the following agents have been shown to be effective in preventing serious influenza-related complications
  • Data is limited concerning effectiveness of the antiviral agents for the treatment of patients at high-risk of serious complications of influenza

Adamantanes

  • Eg Amantadine, Rimantadine
  • Consider local resistance data when prescribing adamantanes for patients with influenza
  • Chemoprophylaxis and treatment against circulating influenza A virus strains using adamantanes are not recommended because of increasing reports of drug resistance
  • Possesses little or no activity against influenza type B virus

Baloxavir marboxil

  • The 1st approved influenza virus-specific enzyme polymerase acidic (PA) protein-targeting drug used for the treatment of acute uncomplicated seasonal influenza in patients ≥12 years old who exhibited symptoms for no more than 48 hours
  • Based on several studies, the therapeutic effect of a single dose of Baloxavir marboxil is comparable to that of the 5-day twice-daily treatment with Oseltamivir

Neuraminidase Inhibitors

  • Eg Oseltamivir, Peramivir, Zanamivir
  • Oral Oseltamivir and inhaled Zanamivir are used for treatment and prophylaxis of infection with influenza A or B viruses
    • Oral Oseltamivir is the antiviral drug of choice for the management of influenza infections in children
      • May be given to premature infants at 3-3.5 mg/kg/dose 12 hourly
    • Inhaled Zanamivir may be used in children ≥7 years old as an alternative treatment for those without any chronic lung disease
  • Intravenous Peramivir can be used for early treatment of acute uncomplicated influenza in nonhospitalized children ≥2 years of age who have been symptomatic for no more than 48 hours
  • Studies are still being conducted on the use of intravenous Zanamivir for seasonal influenza but may be considered in newly emergent Oseltamivir- or Peramivir-resistant virus
  • Effects:
    • As treatment: Can reduce duration of uncomplicated influenza A and B illness by approximately 1 day compared with placebo when used within 2 days of illness onset
    • Both drugs are effective, 82% (Oseltamivir) or 84% (Zanamivir), in preventing febrile, laboratory-confirmed influenza illness in otherwise healthy individuals
  • Combination treatment with neuraminidase inhibitors is not recommended
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.